MiMedx Group develops and markets regenerative biologics derived from human placental tissue for advanced wound care and surgical applications. Flagship allograft products such as EpiFix and AmnioFix are used by clinicians to support healing in chronic wounds, soft-tissue repair, and related procedures. Hospitals, wound centers, and surgical practices are the primary customers for these tissue-based therapies.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 98.6 | — | 9.6 | — |
| Q3 2025 | 113.7 | — | 16.8 | — |
| Q4 2025 | 118.1 | — | 15.2 | — |
| Q1 2026 | 59 | — | -10.9 | — |
| Q2 2026 | 64.4 | -34.7% | -14.8 | -254.3% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: ACNB Corporation (ACNB), Docebo Inc. (DCBO), Frequency Electronics, Inc. (FEIM), Red River Bancshares, Inc. (RRBI), Cognyte Software Ltd. (CGNT), Park-Ohio Holdings Corp. (PKOH)